PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1(st) and 2(nd) generation ALK inhibitors in pre-clinical models

We report the preclinical evaluation of PF-06463922, a potent and brain penetrant ALK/ROS1 inhibitor. Compared to other clinically available ALK inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mutations, including the highly resistant G1202R mutant. Furth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Zou, Helen Y., Friboulet, Luc, Kodack, David P., Engstrom, Lars D., Li, Qiuhua, West, Melissa, Tang, Ruth W., Wang, Hui, Tsaparikos, Konstantinos, Wang, Jinwei, Timofeevski, Sergei, Katayama, Ryohei, Dinh, Dac M., Lam, Hieu, Lam, Justine L., Yamazaki, Shinji, Hu, Wenyue, Patel, Bhushankumar, Bezwada, Divya, Frias, Rosa L., Lifshits, Eugene, Mahmood, Sidra, Gainor, Justin F., Affolter, Timothy, Lappin, Patrick B., Gukasyan, Hovhannes, Lee, Nathan, Deng, Shibing, Jain, Rakesh K, Johnson, Ted W., Shaw, Alice T., Fantin, Valeria R., Smeal, Tod
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4504786/
https://ncbi.nlm.nih.gov/pubmed/26144315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2015.05.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados